While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.
Dr. Jennifer Bath
Advertisement
Dr. Jennifer Bath is an immunologist and cellular and molecular biologist. She is also president and CEO of ImmunoPrecise Therapeutics.
Articles by Dr. Jennifer Bath
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
